Discussion stirs around Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) this week; here is what analysts are saying.

January 19, 2018 - By Richard Conner

 Discussion stirs around Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) this week; here is what analysts are saying.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. As per Monday, August 21, the company rating was maintained by Maxim Group. The firm has “Buy” rating by Raymond James given on Monday, December 4. The stock has “Buy” rating by Maxim Group on Monday, June 12. Raymond James initiated it with “Buy” rating and $7.0 target in Tuesday, September 12 report. Maxim Group initiated Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Tuesday, December 1. Maxim Group has “Buy” rating and $16 target. The stock has “Buy” rating by Maxim Group on Thursday, July 21. Below is a list of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) latest ratings and price target changes.

04/12/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Buy New Target: $9.5
04/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $9.5
12/09/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Initiate
21/08/2017 Broker: Maxim Group Rating: Buy New Target: $13.0 Maintain

The stock increased 2.44% or $0.1 during the last trading session, reaching $4.2. About 399,204 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since January 19, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $140.23 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Another recent and important Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news was published by Seekingalpha.com which published an article titled: “Adamis Pharmaceuticals: A Rocket Still On The Launchpad” on November 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.